

### **TOWARDS ACCESS 2030**

### WHO Medicines and Health Products Programme Strategic Framework 2016 - 2030



## What guides us

# VISION

A world where every child, man and woman has access to the quality essential medicines, vaccines and other health products they need to lead a healthy and productive life.



# 2 strategic roles for stronger health systems

#### **Facilitator**

#### Guardian

Fostering needsbased innovation and reinforcing health products selection, use and supply systems to increase access Strengthening regulatory capacity and practices to ensure the quality, safety and efficacy of products and improve the efficiency of regulatory systems to secure health gains.




### Current challenges in the medicines sector

- High burden of Non Communicable Diseases & unfinished MDG's agenda
- High cost medicines
- Weaknesses of regulatory systems in many countries & SSFFC
- Limited resources both human and financial
  - Affects services, poor retention of qualified staff
- Fragmentation due to vertical disease programs
- Wide range of actors in the pharmaceutical sector



### The pharmaceutical value chain





### Focus on results

#### **1** EFFECTIVE REGULATION

Regulatory guidance adopted in countries, networks established and well-functioning, undertaking joint activities and promoting reliance.

#### 2 QUALITY PRODUCTS

PQ list recognized as a 'brand' and expanded to include products relevant to SDGs

#### **3** NEEDS DRIVEN INNOVATION

New products in the pipeline for neglected tropical diseases, epidemic prone pathogens and AMR

#### **4** INTELLECTUAL PROPERTY


- Patent transparency for all patented essential medicines
- Strategic local/regional manufacture

#### 5 EVIDENCE BASED SELECTION

- More countries effectively using EML, HTA and APL to select health products
- Essential Medical Devices and Diagnostics List and Priority Assistive Products List established and implemented.



### Focus on results





### EC/ACP/WHO Renewed Partnership Result areas selected by countries - Year 4

Result areas	Nb countries /14 (Nb of activities/71)	List of countries
1- Improved availability and supply of selected medicines	8 (10)	Burundi, Congo, DRC, Ghana, Guinea, Senegal, Togo, Zambia
2- Reduced medicines prices and improved mechanism for financing and coverage of essential medicines	5 (6)	Congo, Ethiopia, Ghana, Kenya, Togo
3- Improved quality of medicines and reduced occurrence of substandard medicines	13 (25)	Burundi, Congo, DRC, Ethiopia, Ghana, Guinea, Kenya, Mali, Mozambique, Senegal, Tanzania, Togo, Zambia
4- Improved medicines selection, prescribing, dispensing and use	11 (20)	Burundi, Congo, DRC, Ethiopia, Ghana, Mali, Mozambique, Tanzania, Togo, Zambia, Zimbabwe
5- Improved access to reliable country information, NMP and plans, transparency and good governance	8 (10)	Burundi, DRC, Ghana, Guinea, Kenya, Senegal, Tanzania, Zimbabwe

WHO/HIS/EMP | April 3, 2017

QUALITY


QUALITY


World Health

QUALITY

ganization

# Inefficiencies and unethical practices can occur throughout the medicines supply chain





### Access to essential medicines: an unfinished agenda

- Despite some improvements towards MDGs, problems with access to key essential medicines remain
- Patients with HIV, TB, malaria untreated or sub-optimally treated
- MDR-TB poses significant threats to management of TB
- Unmet needs of mothers and children for essential medicines and reproductive health commodities
- Global challenges of non-communicable diseases; poorest countries are dealing with double burden of communicable and NCDs
- Providing access to cancer therapies and other high cost medicines

QUALITY

WHO/HIS/EMP | April 3, 2017

• Managing responsible use of antimicrobials to deal with problems of antimicrobial resistance

ACCESS

Norld Hea

### Thank you

